Cosmetic and topical
Arkham Labs editorial/Published 8 September 2026/Revised 12 September 2026/Corrections policy
Peptides sold for topical application to skin. This is the family where the gap between marketing volume and published evidence is widest in the whole library — these ingredients appear in thousands of products and none of the four has a randomised human trial behind it.
Four ingredients that appear in thousands of consumer products, thirty-four references between them, and not one randomised human trial in the family.
The unresolved question is the same for all four, and it comes before efficacy: whether the molecule reaches the target it is proposed to act on. Cosmetically active compounds have difficulty reaching deeper skin layers, and whether that permeation can currently be measured at all is openly questioned in the literature. Argireline‘s proposed mechanism has been compared in print to botulinum neurotoxins; the comparison is about the pathway, not about demonstrated effect in skin. SNAP-8 is graded Preclinical as a floor: PubMed’s phrase index returns nothing for the name, and no study of its claimed mechanism for this compound was located.
- Guides in this family
- 4
- Peer-reviewed sources
- 34
- Grades represented
- Preclinical 4
- Argireline◦Preclinical
- Copper Peptide Topicals◦Preclinical
- Matrixyl◦Preclinical
- SNAP-8◦PreclinicalFloor
Cosmetic regulation does not require efficacy evidence, so none was generated. That is a fact about the regulatory category, not about the ingredients — and it cuts both ways.
For laboratory research use only. Not for human consumption. Nothing here is medical advice.